These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 34439767)

  • 1. LRRK2 Targeting Strategies as Potential Treatment of Parkinson's Disease.
    Wojewska DN; Kortholt A
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric inhibition of LRRK2, where are we now.
    Soliman A; Cankara FN; Kortholt A
    Biochem Soc Trans; 2020 Oct; 48(5):2185-2194. PubMed ID: 33079169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRRK2 Structure-Based Activation Mechanism and Pathogenesis.
    Zhang X; Kortholt A
    Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric modulation of the GTPase activity of a bacterial LRRK2 homolog by conformation-specific Nanobodies.
    Leemans M; Galicia C; Deyaert E; Daems E; Krause L; Paesmans J; Pardon E; Steyaert J; Kortholt A; Sobott F; Klostermeier D; Versées W
    Biochem J; 2020 Apr; 477(7):1203-1218. PubMed ID: 32167135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2.
    Blanca Ramírez M; Lara Ordóñez AJ; Fdez E; Madero-Pérez J; Gonnelli A; Drouyer M; Chartier-Harlin MC; Taymans JM; Bubacco L; Greggio E; Hilfiker S
    Hum Mol Genet; 2017 Jul; 26(14):2747-2767. PubMed ID: 28453723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease.
    Tang X; Xing S; Ma M; Xu Z; Guan Q; Chen Y; Feng F; Liu W; Chen T; Chen Y; Sun H
    J Med Chem; 2023 Feb; 66(4):2282-2307. PubMed ID: 36758171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
    Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
    Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2.
    Singh RK; Soliman A; Guaitoli G; Störmer E; von Zweydorf F; Dal Maso T; Oun A; Van Rillaer L; Schmidt SH; Chatterjee D; David JA; Pardon E; Schwartz TU; Knapp S; Kennedy EJ; Steyaert J; Herberg FW; Kortholt A; Gloeckner CJ; Versées W
    Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35217606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients.
    Atashrazm F; Hammond D; Perera G; Bolliger MF; Matar E; Halliday GM; Schüle B; Lewis SJG; Nichols RJ; Dzamko N
    Mov Disord; 2019 Mar; 34(3):406-415. PubMed ID: 30597610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker.
    Perera G; Ranola M; Rowe DB; Halliday GM; Dzamko N
    Sci Rep; 2016 Aug; 6():31391. PubMed ID: 27503089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation.
    Cogo S; Ho FY; Tosoni E; Tomkins JE; Tessari I; Iannotta L; Montine TJ; Manzoni C; Lewis PA; Bubacco L; Chartier Harlin MC; Taymans JM; Kortholt A; Nichols J; Cendron L; Civiero L; Greggio E
    Brain Res; 2022 Mar; 1778():147781. PubMed ID: 35016853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease.
    Zhao Y; Dzamko N
    Drugs; 2019 Jul; 79(10):1037-1051. PubMed ID: 31161537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson's disease: a patent review of the literature to date.
    Morez M; Lara Ordóñez AJ; Melnyk P; Liberelle M; Lebègue N; Taymans JM
    Expert Opin Ther Pat; 2024 Sep; 34(9):773-788. PubMed ID: 39023243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Pathways Involved in LRRK2-Linked Parkinson's Disease: A Systematic Review.
    Ravinther AI; Dewadas HD; Tong SR; Foo CN; Lin YE; Chien CT; Lim YM
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leucine-Rich Repeat Kinase 2 in Parkinson's Disease: Updated from Pathogenesis to Potential Therapeutic Target.
    Chen J; Chen Y; Pu J
    Eur Neurol; 2018; 79(5-6):256-265. PubMed ID: 29705795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
    Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
    Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo.
    Kluss JH; Mazza MC; Li Y; Manzoni C; Lewis PA; Cookson MR; Mamais A
    Mol Neurodegener; 2021 Mar; 16(1):17. PubMed ID: 33741046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play.
    Azeggagh S; Berwick DC
    Br J Pharmacol; 2022 Apr; 179(8):1478-1495. PubMed ID: 34050929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L'RRK de Triomphe: a solution for LRRK2 GTPase activity?
    Nixon-Abell J; Berwick DC; Harvey K
    Biochem Soc Trans; 2016 Dec; 44(6):1625-1634. PubMed ID: 27913671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.